ClinicalTrials.gg
RecruitingNCT07245095NACSIMETUpdated Nov 24, 2025

Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy

A Phase 2 interventional study of Premedication with n-acetylcysteine and Placebo (drinking water) in Esophagogastroduodenoscopy, Simethicone and N-Acetylcysteine, sponsored by Hospital General de Mexicali. Recruiting at 2 sites in Mexico. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Hospital General de Mexicali · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Stomach Neoplasms with a site in Mexico — 2 open to participants now, 4 under way, 3 of them phase 3. Stomach Neoplasms · Mexico.

Planned enrollment
19th of 22
132 · median 565
Started
2025
the only one that year
Phase 2
3 of 26
1 open now
Registered
25th of 26
by date
Lead sponsor
1 of 26
Hospital General de Mexicali

Among the 26 studies in Stomach Neoplasms with a site in Mexico, this one is the 19th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 25th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

2 of the 26 studies in Stomach Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Stomach Neoplasms with a site in Mexico, or all of them as a file.
02

Study summary

The goal of this randomized, double-blind, placebo-controlled clinical trial is to assess whether the combination of N-acetylcysteine and simethicone improves mucosal visibility during upper gastrointestinal endoscopy in adults aged 18 to 99 years of both sexes, including both healthy individuals and those with non-bleeding gastrointestinal symptoms.

The main questions this study aims to answer are:

Does pre-endoscopy administration of N-acetylcysteine/simethicone improve mucosal visualization based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS)?

Is this combination safe and well tolerated in this patient population?

Researchers will compare patients receiving N-acetylcysteine (600 mg) and simethicone (100 mg) orally 20-60 minutes before the procedure with those receiving placebo (water) to determine if there is a significant improvement in TUGS scores.

Participants will:

Receive a single oral dose of either N-acetylcysteine/simethicone or placebo prior to endoscopy

Undergo a routine upper GI endoscopy

Have mucosal cleanliness evaluated using the TUGS scoring system

Be monitored for any adverse events or intolerance

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial designed to evaluate the efficacy of N-acetylcysteine (NAC) combined with simethicone in improving mucosal visibility during upper gastrointestinal endoscopy (UGIE). The evaluation will be based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS), a validated tool to assess mucosal cleanliness.

Participants will include adult patients aged 18 to 99 years who are scheduled to undergo diagnostic UGIE for various indications and who do not present with active gastrointestinal bleeding. Eligible participants will be randomized to receive either a single dose of NAC (600 mg) plus simethicone (100 mg) or a placebo (water), administered orally 20 to 60 minutes prior to the procedure. The allocation will be blinded to both participants and endoscopists.

The main objective of the study is to determine whether this premedication protocol results in better mucosal visibility, as measured by the total TUGS score. Secondary objectives include documenting the presence of significant endoscopic findings and histopathological diagnoses, and evaluating the tolerability and safety profile of the premedication.

TUGS scores will be assigned by trained endoscopists blinded to the treatment allocation. Variables such as age, sex, BMI, duration of fasting, hospital site, and endoscope model will be recorded and controlled for in statistical analyses. The study will also assess any potential adverse events associated with the administration of NAC/simethicone.

This study is categorized as Phase 2 because it evaluates the preliminary efficacy and short-term safety of pre-procedural oral N-acetylcysteine (NAC) and simethicone to improve mucosal visibility during diagnostic upper gastrointestinal endoscopy, using the Toronto Upper Gastrointestinal Cleaning Score (TUGCS) as a validated surrogate endpoint. Both agents have established safety profiles for other indications, but their combined use for this indication is not an approved or established standard of care. The trial is randomized, double-blind, placebo-controlled with a moderate sample size designed to estimate effect size and variability rather than to deliver definitive, multi-center confirmatory evidence on hard clinical outcomes.

All procedures will adhere to ethical standards, and informed consent will be obtained from all participants. Data will be collected in a coded, anonymized format and analyzed using appropriate statistical methods, including ANCOVA and non-parametric tests where assumptions of normality are not met.

03

Conditions studied

  • Esophagogastroduodenoscopy
  • Simethicone
  • N-Acetylcysteine
  • Premedication
  • Visualization
  • Esophagogastroduodensocopy (EGD) Procedure
  • Placebo - Control
  • Gastritis Associated With Helicobacter Pylori
  • Tumor Gastric
  • Lesions in the Esophagus, Stomach, Duodenum or Rectum

Browse trials for

Keywords

  • Esophagogastroduodenoscopy
  • Mucous Membrane
  • Premedication
  • Simethicone
  • Acetylcysteine
  • Gastrointestinal Tract
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 to 70 years old.
  • Patients who agree to participate in the clinical trial.
  • Patients without active gastrointestinal bleeding.
  • Signing of form.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of to N-acetylcysteine
  • Patients with a history of hypersensitivity to simethicone
  • Patients with a previous endoscopic diagnosis
  • Patients with a history of gastric or bariatric surgery
  • Patients with a history of motor disorders (e.g., scleroderma, diabetic gastroparesis)
  • Patients taking medications that delay gastric emptying (GLP-1 analogues)
  • Pregnant or breastfeeding patients
  • Patients who do not agree to participate in the clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
132 participants (estimated)

Study arms

  • Active comparator
    Patients receiving n-acetylcysteine/simethicone

    Drug: Premedication with n-acetylcysteine · Drug: Premedication with simethicone

  • Placebo comparator
    Patients receiving placebo

    Drug: Placebo (drinking water)

Interventions

  • DrugPremedication with n-acetylcysteine

    Once the sample size has been calculated, patients who meet the inclusion criteria will be recruited. who will be randomized using the "Randomized for Clinical Trial" program for assignment to treatment groups A and B. Group A will receive 600 mg of N-acetylcysteine and 100 mg of simethicone orally 20 to 60 minutes before the procedure, while the control group will receive an equivalent placebo infusion (composed of drinking water). Premedication and placebo will be labeled in containers as medication or placebo by external personnel not involved in the study, and the identification of each bag will be noted on a sheet and kept in an envelope that will be opened at the end of the study. Tolerance will be evaluated. If any adverse events are identified, the principal investigator will be notified for action regarding the management of the adverse event and its reporting.

  • DrugPlacebo (drinking water)

    The control group will receive an equivalent placebo infusion (composed of drinking water)

  • DrugPremedication with simethicone

    Once the sample size has been calculated, patients who meet the inclusion criteria will be recruited. who will be randomized using the "Randomized for Clinical Trial" program for assignment to treatment groups A and B. Group A will receive 600 mg of N-acetylcysteine and 100 mg of simethicone orally 20 to 60 minutes before the procedure, while the control group will receive an equivalent placebo infusion (composed of drinking water). Premedication and placebo will be labeled in containers as medication or placebo by external personnel not involved in the study, and the identification of each bag will be noted on a sheet and kept in an envelope that will be opened at the end of the study. Tolerance will be evaluated. If any adverse events are identified, the principal investigator will be notified for action regarding the management of the adverse event and its reporting

06

What researchers measure

Primary outcomes

  1. Total score on the Toronto Upper Gastrointestinal Cleaning Score (TUGCS)

    The Toronto Upper Gastrointestinal Cleaning Score (TUGCS) is a validated scale that assesses mucosal cleanliness/visualization across four upper GI areas (fundus, body, antrum, and duodenum). Each area is scored from 0 to 3 (0 = poorest visualization; 3 = entire mucosa visible without suctioning/washing). The total score is the sum of all four areas (range 0-12). Higher scores indicate better mucosal cleanliness/visibility. Scoring is performed by blinded assessors during the procedure using standardized criteria.

    Time frame: During the index upper endoscopy (Day 0), scored intra-procedure (≈20-60 minutes after premedication).

Secondary outcomes

  1. Detection of Mucosal Lesions

    Number of patients in whom mucosal lesions are detected during the procedure.

    Time frame: During endoscopy procedure

  2. Complete Esophageal Visualization

    Binary assessment (Yes/No) of whether complete esophageal visualization was achieved.

    Time frame: During endoscopy.

  3. Histological gastritis according to the Updated Sydney System (0-3 per item) and OLGA/OLGIM staging (0-IV)

    Measurement tool: Updated Sydney System (sum of domains not mandatory). Sites and technique: 5 gastric biopsies according to the Sydney protocol (2 antrum, 2 body, 1 incisura angularis), fixed in formalin; H\&E and Giemsa staining (or IHC if necessary for H. pylori). Domains and ranges (each 0-3): H. pylori density: 0 = absent, 1 = mild, 2 = moderate, 3 = marked. Chronic inflammation (mononuclear): 0-3. Activity (neutrophils): 0-3. Glandular atrophy: 0-3. Intestinal metaplasia: 0-3. Minimum-maximum range per domain: 0-3; higher scores = worse histological severity. Risk staging: OLGA (0-IV) for atrophy, OLGIM (0-IV) for intestinal metaplasia; higher stages = worse stage/higher risk. Reported measure: distribution of scores per domain (0-3) and proportion per OLGA/OLGIM stage (0-IV), comparing arms.

    Time frame: Biopsies obtained during the index endoscopy (Day 0); histopathological report within 14 days

  4. Presence and density of Helicobacter pylori by histology (Updated Sydney System 0-3)

    Measurement tool: Updated Sydney System for H. pylori. Range and direction: 0-3 (0 = not detected; 1 = mild; 2 = moderate; 3 = marked). Higher scores = higher bacterial density. Technique: H\&E + Giemsa staining (or IHC if indeterminate). Reported measure: Proportion of patients positive for H. pylori (≥1 on the scale), and Distribution of categories 0-3 per arm.

    Time frame: Biopsies obtained during the index endoscopy (Day 0); report within 14 days

  5. Number of histologically confirmed neoplasic lesions per patient

    Higher values reflect higher detection performance; this should be interpreted in conjunction with the detection rate (NDR)

    Time frame: During the index endoscopy (Day 0) and histological confirmation up to 14 days

07

Study locations

2 of 2 sites recruiting
  • Hospital Almater
    Mexicali, Estado de Baja California 21000, Mexico
    Recruiting
  • Hospital General de Mexicali
    Mexicali, Estado de Baja California 21100, Mexico
    Recruiting
08

References and documents

Publications

  • Devereaux BM, Taylor ACF, Athan E, Wallis DJ, Brown RR, Greig SM, Bailey FK, Vickery K, Wardle E, Jones DM. Simethicone use during gastrointestinal endoscopy: Position statement of the Gastroenterological Society of Australia. J Gastroenterol Hepatol. 2019 Dec;34(12):2086-2089. doi: 10.1111/jgh.14757. Epub 2019 Jul 28. PubMed 31242327 ↗
  • Manfredi G, Berte R, Iiritano E, Alicante S, Londoni C, Brambilla G, Romeo S, Menozzi F, Griffanti P, Brandi G, Moreschi O, Pezzilli R, Zullo A, Buscarini E. Premedication with simethicone and N-acetylcysteine for improving mucosal visibility during upper gastrointestinal endoscopy in a Western population. Endosc Int Open. 2021 Feb;9(2):E190-E194. doi: 10.1055/a-1315-0114. Epub 2021 Jan 25. PubMed 33532557 ↗
  • Monrroy H, Vargas JI, Glasinovic E, Candia R, Azua E, Galvez C, Rojas C, Cabrera N, Vidaurre J, Alvarez N, Gonzalez J, Espino A, Gonzalez R, Parra-Blanco A. Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial. Gastrointest Endosc. 2018 Apr;87(4):986-993. doi: 10.1016/j.gie.2017.10.005. Epub 2017 Oct 14. PubMed 29037773 ↗
  • Beaufort IN, Verbeek RE, Bosman JH, Al-Toma A, Bogte A, Alvarez Herrero L, Weusten BLAM. Optimal timing of simethicone administration prior to upper endoscopy: A multicenter, single-blind, randomized controlled trial. Endosc Int Open. 2023 Oct 17;11(10):E992-E1000. doi: 10.1055/a-2157-5034. eCollection 2023 Oct. PubMed 37854124 ↗
  • Mahawongkajit P, Kanlerd A. A prospective randomized controlled trial comparing simethicone, N-acetylcysteine, sodium bicarbonate and peppermint for visualization in upper gastrointestinal endoscopy. Surg Endosc. 2021 Jan;35(1):303-308. doi: 10.1007/s00464-020-07397-8. Epub 2020 Feb 3. PubMed 32016519 ↗
  • Chang WK, Yeh MK, Hsu HC, Chen HW, Hu MK. Efficacy of simethicone and N-acetylcysteine as premedication in improving visibility during upper endoscopy. J Gastroenterol Hepatol. 2014 Apr;29(4):769-74. doi: 10.1111/jgh.12487. PubMed 24325147 ↗
  • Sajid MS, Rehman S, Chedgy F, Singh KK. Improving the mucosal visualization at gastroscopy: a systematic review and meta-analysis of randomized, controlled trials reporting the role of Simethicone +/- N-acetylcysteine. Transl Gastroenterol Hepatol. 2018 May 19;3:29. doi: 10.21037/tgh.2018.05.02. eCollection 2018. PubMed 29971260 ↗
  • Li Y, Du F, Fu D. The effect of using simethicone with or without N-acetylcysteine before gastroscopy: A meta-analysis and systemic review. Saudi J Gastroenterol. 2019 Jul-Aug;25(4):218-228. doi: 10.4103/sjg.SJG_538_18. PubMed 31044749 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data related to baseline demographics, Toronto Upper Gastrointestinal Cleaning Score (TUGS), endoscopic findings, and histopathological results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be available beginning 6 months after publication of the main results and for up to 3 years thereafter.

Access criteria: Researchers whose proposed use of the data has been approved by the study's principal investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Nov 2026, 14 months after the start.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 14 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Nov 24, 2025
StartActual
Sep 12, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07245095
Lead sponsor
Hospital General de Mexicali
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Sep 12, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Luis Andre Sanchez Perez, Resident
Contact
sanchez.luis3@uabc.edu.mx
+ 52 6863468689
Jesus Alberto Camacho Escobedo, Gastroenterologist
Contact
jesus13camacho@hotmail.com
+ 52 6862146050

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion